Immunotherapy tackles precancerous mouth spots

NCT ID NCT03603223

First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This trial tests whether pembrolizumab (Keytruda), an immunotherapy drug that helps the immune system attack abnormal cells, can shrink or control leukoplakia—a precancerous condition of the mouth. The study includes people with leukoplakia or related lesions that cannot be removed by surgery or who have declined surgery. Researchers will measure how many participants respond to treatment over six months and look for factors that might predict better outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Pembrolizumab (Keytruda)
What this could lead to
If it works, this could point toward a non-surgical treatment option for leukoplakia, potentially reducing the risk of it turning into cancer.
What could go wrong
This is a small, early-phase trial with only 26 participants, so results may not apply broadly. Pembrolizumab can cause immune-related side effects like inflammation in healthy organs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ERYTHROLEUKOPLAKIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • UC San Diego Moores Cancer Center

    NOT_YET_RECRUITING

    La Jolla, California, 92093, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • UCLA / Jonsson Comprehensive Cancer Center

    RECRUITING

    Los Angeles, California, 90095, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • USC / Norris Comprehensive Cancer Center

    NOT_YET_RECRUITING

    Los Angeles, California, 90033, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.